anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: We have recently shown that readmission after EGS procedures carries a 4-fold higher mortality rate when compared to those not readmitted. Understanding factors associated with death after readmission is paramount to improving outcomes for EGS patients. We aimed to identify risk factors contributing to failure-to-rescue (FTR) during readmission after EGS. We hypothesized that most post-readmission deaths in EGS are attributable to FTR.
METHODS: A retrospective cohort study using the NSQIP database 2013-2019 was performed. Patients who underwent 1 of 9 urgent/emergent surgical procedures representing 80% of EGS burden of disease, who were readmitted within 30 days post-procedure were identified. The procedures were classified as low- and high-risk. Patient characteristics analyzed included age, sex, BMI, ASA score comorbidities, postoperative complications, frailty, and FTR. The population was assessed for risk factors associated with mortality and FTR by uni- and multivariate logistic regression.
RESULTS: Of 312,862 EGS cases, 16,306 required readmission. Of those, 10,748 (3.4%) developed a postoperative complication. Overall mortality after readmission was 2.4%, with 90.6% of deaths attributable to FTR. Frailty, high-risk procedures, pulmonary complications, AKI, sepsis, and the need for reoperation increased the risk of FTR.
DISCUSSION: Death after a complication is common in EGS readmissions. The impact of FTR could be minimized with the implementation of measures to allow early identification and intervention or prevention of infectious, respiratory, and renal complications.
Use of polycationic compound (I) as a direct dye in tinctorial compositions (A) for keratinous fibers (preferably human keratinous fibers e.g. hair) or for the manufacture of (A). Use of a polycationic compound of formula (I) as a direct dye in tinctorial compositions (A) for keratinous fibers (preferably human keratinous fibers such as hair) or for the manufacture of (A). Xzaorganic or mineral anion; z, za : such as to make the whole charge of the compound neutral;; A : heterocyclic (carrying a positive charge) optionally substituted with thiazolium, imidazolium, benzimidazolium, benzothiazolium pyridine, naphthothiazolium or benzothiazolium; B : 6-30C arylene or 5-10C heterocyclic group (both optionally substituted); L : optionally substituted 1-30C alkylene (optionally interrupted or terminated by one or more heteroatoms such as O, S, NH or NR or interrupted by one or more cyclic, optionally aromatic, optionally heterocyclic radicals (carrying one or more quaternary cationic charges and one or more carbon atoms, where the chain is replaced by a carbonyl group)); and R1>, R2>, R3>1-10C linear alkyl optionally substituted by two or more radicals formed with the nitrogen atom carrying a saturated heterocycle with 5-10 chains optionally substituted by one or more additional heteroatoms. Independent claims are also included for: (1) (A) comprising at least an oxidation base and (I) in a dyeing medium; and (2) a process of dyeing of keratinous fibers comprising applying (A) on keratinous fibers, allowing the fibers to remain for 5 minutes to an hour (preferably 15 minutes-1> hour). [Image].
Disclosed herein is a device for managing a spread of infectious diseases among users. Further, the device comprises a communication device, a location sensor, a pathogen tracer microcontroller device, an output device, and a storage device. Further, the communication device receives device data from devices. Further, the location sensor generates location data based on a location of the device corresponding to a time period. Further, the pathogen tracer microcontroller device analyzes the device data and the location data, determines a spatiotemporal proximity of the device to the devices, compare the spatiotemporal proximity with a predetermined spatiotemporal proximity, determines a risk of the spread of a pathogen causing an infectious disease between the users, and generates an alert. Further, the output device produces alert signals based on the alert. Further, the storage device stores the alert and a status of a user corresponding to the infectious disease.
A clinical observational study will be performed in women admitted at the Department of Obstetrics at the Sophia Children's Hospital/Erasmus MC for suspicion of preterm birth with a gestational age of 23+5 weeks until 33+6 weeks. Antenatal corticosteroids will be administered according to the local standard protocol (12 mg betamethasone intramuscular with a 24 hours intervall). Importantly, clinical management of women with suspicion of preterm birth will not be affected by the proposed study. After inclusion, repetitive blood sampling according to the following schedule: t0 (administration), t0-30 min, t10-12hrs and t20-24 hrs. Umbilical cord will be sampled directly after birth as fetal determinant in which corticosteroids and their metabolites will be measured. Also, neonatal blood samples (drawn by the paediatricians as part of standard care) will be used for measurement of corticosteroids and their metabolites. Maternal blood samples will furthermore be analysed for determinants effecting pharmacokinetics such as oestradiol.
Background: Relations among attention-deficit/hyperactivity disorder (ADHD), sleep, and substance-related negative consequences are largely unknown. In this cross-sectional study, we examined associations among ADHD diagnosis, sleep, and alcohol-related consequences. We also evaluated the independent and interactive effects of sleep and ADHD on alcohol-related negative consequences, above and beyond levels of alcohol use. Methods: College students who drink alcohol with (n = 51) and without (n = 50) ADHD completed an assessment that included a diagnostic interview assessing ADHD, and questionnaire measures of sleep quality, substance use, and associated consequences. Analyses utilized a series of hierarchical linear regression models and explored these aims for cannabis use in a subset of participants (n = 52 participants that used cannabis). Results: College students who drink alcohol with ADHD reported significantly worse sleep quality and more alcohol-related consequences, relative to those without ADHD. When ADHD and sleep quality were included in the model, ADHD-but not sleep quality-was independently associated with alcohol consequences, but not cannabis consequences. There were no moderating effects of ADHD on the associations between sleep and substance-related consequences. Conclusions: Students who drank alcohol with ADHD may be particularly vulnerable to experiencing poor sleep and consequences from their substance use, compared to their heavy drinking peers without ADHD. Future, larger scale studies should consider longitudinal effects as well as underlying mechanisms of risk.
Assay for protein induced by vitamin K absence-II (PIVKA-II) is by the enzyme immunoassay method with 2 antiody sandwiching.  A monoclonal anti-PIVKA-II antibody is used as solidified antibody for the assay.  PIVKA-II is obtd. from the plasma of patients taking warfarin by adsorption on BaSO4, followed by ion exchange on cellulose.  Then affinity chromatography on a column is which the monoclonal antibody is common in part to normal prothrombin and PIVKA-II is used.  Elution with guanidine HCl, dialysis and concn. gives PIVKA-II.  Then the PIVKA-II is used to produce monoclonal antibody by using mice, with the usual fusion and selection procedures.
Pts will receive 2 doses of ipilimumab 3mg/kg + nivolumab 1mg/kg every 3 weeks. Week 6, if pts have achieved a favorable antitumor effect by RECIST will begin maintenance nivolumab alone at 480mg every 4 weeks for 2 doses (week 6 \& week 10) \& repeat response assessments at week 12. If pts don't achieve a favorable antitumor effect at week 6, pt will get 2 additional doses of ipilimumab + nivolumab every 3 weeks \& then will be assessed for response at week 12. If pts haven't achieved a favorable antitumor effect by week 12, if felt in the best interest for the pt as determined by the PI, pts may continue getting additional doses of ipilimumab + nivolumab with response reassessments after every 2 doses. Maintenance nivolumab will continued until unacceptable toxicity or confirmed disease progression. If pts have had an initial clinical benefit from therapy \& subsequently experience progressive disease at any time, reinduction with combination ipilimuma+ nivolumab will be allowed.
Background Globally, frailty is associated with a high prevalence of avoidable hospital admissions and emergency department visits, with substantial associated healthcare and personal costs. International guidelines recommend incorporation of frailty identification and care planning into routine primary care workflow to support patients who may be identified as pre-frail/frail. Our study aimed to: (1) determine the feasibility, acceptability, appropriateness and determinants of implementing a validated FRAIL Scale screening Tool into general practices in two disparate Australian regions (Sydney North and Brisbane South); and (2) map the resources and referral options required to support frailty management and potential reversal. Methods Using the FRAIL Scale Tool, practices screened eligible patients (aged ≥75years) for risk of frailty and referred to associated management options. The percentage of patients identified as frail/pre-frail, and management options and referrals made by practice staff for those identified as frail/pre-frail were recorded. Semi-structured qualitative interviews were conducted with practice staff to understand the feasibility, acceptability, appropriateness and determinants of implementing the Tool. Results The Tool was implemented by 19 general practices in two Primary Health Networks and 1071 consenting patients were assessed. Overall, 80% of patients (n =860) met the criterion for frailty: 33% of patients (n =352) were frail, and 47% were pre-frail (n =508). They were predominantly then referred for exercise prescription, medication reviews and geriatric assessment. The Tool was acceptable to staff and patients and compatible with practice workflows. Conclusions This study demonstrates that frailty is identified frequently in Australians aged ≥75years who visit their general practice. It's identification, linked with management support to reverse or reduce frailty risk, can be readily incorporated into the Medicare-funded annual 75+ Health Assessment.
Participants with Post-treatment Lyme Disease (PTLD) will start with 40 sessions (i.e., 4 weeks of Monday to Friday, twice daily treatments that last 1 hour each session) to receive transcutaneous auricular Vagus Nerve Stimulation (taVNS). If compliance is less than 70% in at least 3 of the first 4 open label treated participants, then the investigators will modify the treatment design accordingly.
The present invention relates to host cells transformed with a nucleic acid sequence encoding a eukaryotic xylose  isomerase obtainable from an anaerobic fungus. When expressed, the sequence encoding the xylose isomerase confers to the host  cell the ability to convert xylose to xylulose which may be further metabolised by the host cell. Thus, the host cell is capable of  growth on xylose as carbon source. The host cell preferably is a eukaryotic microorganism such as a yeast or a filamentous fungus.  The invention further relates to processes for the production of fermentation products such as ethanol, in which a host cell of the  invention uses xylose for growth and for the production of the fermentation product. The invention further relates to nucleic acid  sequences encoding eukaryotic xylose isomerases and xylulose kinases as obtainable from anaerobic fungi.
The invention relates to antiviral powder for livestock and poultry and capable of clearing heat and removing toxicity. The antiviral powder shows good effects on clearing heat and removing toxicity. The powder is prepared through the following steps of: taking 60 parts by weight of isatis root, 60 parts by weight of astragalus membranaceus, 30 parts by weight of herba epimedii, and 10 to 16 parts by weight of rheum officinale; crushing the medicines above; sieving; and uniformly mixing to obtain the powder. The antiviral powder is characterized in that the formula is improved, rheum officinale generally used for treating coagulated cold by purgation and purging fire for removing toxin is added, thus loose bowels and dysentery of livestock and poultry are avoided, and a remarkable effect on treating fever of livestock and poultry is brought. With the adoption of the antiviral powder, the body energy and vitality of livestock and poultry are ensured; the medicines naturally have the effect of improving the immunity, so that the antiviral capacity can be obviously improved, the virus infection rate of livestock and poultry can be obviously reduced, and livestock and poultry can grow well; the antibiotics are avoided, and thus the problems due to drug resistance and reduction of immunity of livestock and poultry can be reduced. The antiviral powder is convenient for clinical use and can reduce the cultivation cost.
FIELD: chitin derivative technology. SUBSTANCE: method comprises preparing acidic aqueous chitosan solution, removing undissolved chitosan particles via filtration or precipitation, and modifying chitosan. In that process, chitosan solution freed of undissolved particles is dispersed in presence of hydrophobic surfactant and acetone using mixing at speed no lower than 1000 rpm. Resultant emulsion is modified with organic acid anhydride or dicarboxylic acid dichloride continuing mixing at the same speed to give chitosan emulsion with spherical granule size no more than 100 nm. Preparation of chitosan gel and chitosan suspension from modified chitosan emulsion are also described. EFFECT: reduced size of chitosan granules in gel and emulsion. 9 cl, 9 ex
PURPOSE:To obtain an agent for treating skin itchiness, especially an agent effective against skin itchiness of the patient of chronic renal failure (especially patient subjected to maintenance dialysis) and aged person by using a fat emulsion known as a nutrient infusion for medical use. CONSTITUTION:The objective agent for the treatment of skin itchiness is composed of a fat emulsion (especially preferably an O/W-type emulsion) obtained by properly adding an emulsifying assistant to a mixture of an oil component (e.g. soybean oil), a nonionic surfactant, an emulsifier (e.g. phospholipid) and water. The fat emulsion has an O/W-type structure in general and, in this case, the particle diameter is preferably <=1mum. The agent is administered by parenteral administration (e.g. injection), especially by intravenous injection (injection to the vein-side of the dialysis circuit in the case of a patient of maintenance dialysis). The fat emulsion of 5-30% concentration is administered in an amount of 100-1,000ml once a day or 1-4 times a week.
Vitamin D deficiency can escalate prematurity bone disease in preterm infants and negatively influence their immature immunology system. Infants born at 24+0/7 weeks to 32+6/7 weeks of gestation will be considered for inclusion. Cord or vein blood samples will be obtained within 48 h after birth for 25-hydroxyvitamin D level measurements. Parathyroid hormone and interleukin-6 levels will be measured. Infants will be randomized to the monitored group (i.e., initial dose of 1000 IU/day and possible modification) or the controlled group (i.e., 250 IU/day or 500 IU/day dose, depending on weight). Supplementation will be monitored up to postconceptional age 35 weeks. The primary endpoint is the percentage of infants with deficient or suboptimal 25-hydroxyvitamin D levels at 28±2 days of age. 25-Hydroxyvitamin D levels will be measured at postconceptional age 35±2 weeks. Secondary objectives include the incidence of sepsis, osteopenia, hyperparathyroidism, and elevated interleukin-6 concentration. The aim of this study will be to assess the effectiveness of monitored vitamin D supplementation in a population of preterm infants and to determine whether a high initial dose of monitored vitamin D supplementation in preterm infants can reduce the incidence of neonatal sepsis and incidence of metabolic bone disease.
The invention provides healthcare Puer tea with the function of anti-HIV and improving the immunity. The healthcare Puer tea comprises the components with the following mass ratio: 30 to 50 percent of Puer tea, 10 to 20 percent of dendrobium, 10 to 20 percent of ginseng, 5 to 10 percent of tuckahoe, 10 to 20 percent of rhizoma gastrodiae and 8 to 18 percent of lucid ganoderma. The tea is post-fermentation tea, in the process of fermentation, in addition to the nutrient solution of biological enzyme is added, the fungal substance including Lucid Ganoderma and Rhizoma Gastrodiae as well as the medicine with refreshing and invigorating qi is added. Besides of the function of alleviating the damage on the immune cell, promoting the restore of the impaired immune cell, adjusting the absorptionenvironment of intestinal tract and improving the immune system of human body and the gastrointestinal absorption, the invention has the important function of the strong inhibition role on AIDS virusi.e. HIV. Based on the clinical observation, the invention can reduce the occurrence rates of toxic and the side effects caused by the anti-medicine taken by patients, especially the gastrointestinalsymptoms and the liver toxicity, promote the medication compliance of patients, significantly increase the number of human CD4 immune cells, do not has the toxic and side effects, thereby promoting the efficacy of anti-virus therapy.
The control group's yards will not be modified. Control group receives inorganic fertilizers, moss remover and ant control insecticide (Myrr®; active ingredient imidacloprid 0.03 % w/w).
This study will use an unequally allocated between-subjects (N=30) randomized, controlled design to investigate the influence of complimentary electronic nicotine delivery system (ENDS) provision on combustible cigarette and ENDS use, cigarette dependence, pulmonary function, clinical indicators and biomarkers, and substitution of smoking for ENDS use over 16 weeks. Participants will be adults from the local community with persistent asthma symptoms who are regular combustible cigarette smokers and do not also regularly use ENDS. The study will recruit 30 non-treatment seeking participants using flyers, advertisements, a website triaging visitors to the Center for Alcohol and Addiction Studies, and through targeted recruitment at community immunology clinic partners at Rhode Island Hospital as facilitated by mentor McQuaid. Participants meeting eligibility criteria will be assessed at baseline and then randomized to one of two study conditions: a complimentary ENDS provision condition or assessment-only control. Participants will return for eight weekly visits to complete follow-up assessments; participants in the experimental condition will be provided with additional e-liquid cartridges for their ENDS devices at all follow-up visits. Tobacco use behaviors (cigarette and ENDS) and lung function will be assessed at each visits, with additional collection of biological samples and assessments of nicotine dependence, self-efficacy for cessation, and mood at week eight. Provision of complimentary ENDS will discontinue eight weeks after enrollment. Participants will complete a remote follow-up assessment sixteen weeks after enrollment. This project, and all projects at the Center for Addiction and Disease Risk Exacerbation (CADRE) are supported by the Clinical Laboratory Core (CLC) which will oversee the collection and storage of data and biological samples.
The enzyme, which is able to decompose a high molecular carbohydrate, abbreviated SPS (soluble polysaccaride), is designated SPS-ase. The SPS-ase is able to decompose SPS into decomposition products which attach themselves to protein in an aqueous medium to a lesser extent than the SPS prior to decomposition. The method for selection of SPS-ase producing microorganisms is based on the fact that the main carbon source of a growth medium is SPS and on a qualitative SPS-agar plate test. A method for production of an SPS-ase by means of a deposited strain of Asp. aculeatus is described. The SPS-ase also has utility in the fruit and vegetable industry and for production of juice and wine.
Options for salvage chemotherapy are limited to the following: Low-dose Cytarabine (LoDAC) will be administered twice daily by subcutaneous or intravenous injection for 10 days. Mitoxantrone, Etoposide, Cytarabine (MEC Induction Chemotherapy) will each be administered intravenously for 5 days (days 1 through 5). Granulocyte colony-stimulating factor (G-CSF) will be administered intravenously for 5 days (days 1 through 5) and also recommended 7 days after completing chemotherapy, Fludarabine and Cytarabine administered intravenously for 5 days (days 2 through 6) (FLAG Induction Chemotherapy). Based on the outcome of interim analysis, participants will be evaluated for eligibility for crossover extension (COE). In COE participants will be administered ASP2215 orally once daily.
Folate plays a role in the prevention of certain birth defects and possibly also in prevention of neurocognitive diseases, cancer and cardiovascular disease. The proportion of dietary folate that is absorbed and becomes available for metabolic processes in the body has been estimated between 30 and 98%, but an accurate figure is lacking. Since subjects generally differ a lot in their folate or homocysteine response upon a change in dietary folate intake, the between-person variability in these responses is high. Therefore, bioavailability estimates derived from these responses have large confidence intervals. With this trial the researchers want to determine folate bioavailability with a higher precision than previous trials. A good estimate of folate bioavailability from the general diet is necessary to construct reliable dietary reference intakes for folate.
OBJECTIVES: To investigate the value of conventional ultrasonography (US) combined with quantitative shear wave elastography (SWE) in evaluating and identifying target axillary lymph node (TALN) for fine needle aspiration biopsy (FNAB) of patients with early breast cancer.
MATERIALS AND METHODS: A total of 222 patients with 223 ALNs were prospectively recruited from January 2018 to December 2021. All TALNs were evaluated by US, SWE and subsequently underwent FNAB. The diagnostic performances of US, SWE, UEor (either US or SWE was positive) and UEand (both US and SWE were positive), and FNAB guided by the above four methods for evaluating ALN status were assessed using receiver operator characteristic curve (ROC) analyses. Univariate and multivariate logistic regression analyses used to determine the independent predictors of axillary burden.
RESULTS: The area under the ROC curve (AUC) for diagnosing ALNs using conventional US and SWE were 0.69 and 0.66, respectively, with sensitivities of 78.00% and 65.00% and specificities of 60.98% and 66.67%. The combined method, UEor, demonstrated significantly improved sensitivity of 86.00% (p < 0.001 when compared with US and SWE alone). The AUC of the UEor-guided FNAB [0.85 (95% CI, 0.80-0.90)] was significantly higher than that of US-guided FNAB [0.83 (95% CI, 0.78-0.88), p = 0.042], SWE-guided FNAB [0.79 (95% CI, 0.72-0.84), p = 0.001], and UEand-guided FNAB [0.77 (95% CI, 0.71-0.82), p < 0.001]. Multivariate logistic regression showed that FNAB and number of suspicious ALNs were found independent predictors of axillary burden in patients with early breast cancer.
CONCLUSION: The UEor had superior sensitivity compared to US or SWE alone in ALN diagnosis. The UEor-guided FNAB achieved a lower false-negative rate compared to FNAB guided solely by US or SWE, which may be a promising tool for the preoperative diagnosis of ALNs in early breast cancer, and had the potential implication for the selection of axillary surgical modality.